NBRV News and Press, Nabriva Therapeutics plc From 12/22/21

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it int...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroed...

Nabriva Therapeutics (NBRV) announces that its partner, Sumitomo Pharmaceuticals’ new drug application (NDA) to market oral and intravenous (IV) formulations of lefamulin for the treatment of community-acquired pneumonia (CAP) in adults has been accepted for review in China. "This is t...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced the oral formula...

The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2021 Q3 earnings call. For further details see: Nabriva Therapeutics plc 2021 Q3 - Results - Earnings Call Presentation

Nabriva Therapeutics plc (NBRV) Q3 2021 Results Conference Call November 09, 2021 04:30 PM ET Company Participants Theodore Schroeder - Chief Executive Officer Dan Dolan - Chief Financial Officer Steve Gelone - President and Chief Operating Officer Conference Call Participants Carl Byrnes - N...

Nabriva Therapeutics (NASDAQ:NBRV): Q3 GAAP EPS of -$0.21 beats by $0.01. Revenue of $8.9M (+589.9% Y/Y) beats by $0.01M. Press Release For further details see: Nabriva Therapeutics EPS beats by $0.01, beats on revenue

-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Eastern Time- ...

DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroed...